XVIVO Perfusion AB has carried out a primary issuance of shares of approximately SEK 250 million at a subscription price of SEK 335 per share. The subscription price was determined through an accelerated book-building procedure.

XVIVO is a medical technology company focused on developing optimized solutions for organ, tissue and cell preservation and perfusion in connection with transplantation.

Carnegie and Bryan, Garnier & Co acted as Joint Bookrunners. Baker McKenzie acted as legal advisor to the Joint Bookrunners with an international Capital Markets team consisting of Joakim Falkner, Johanna Flink and Carl Bohman in Stockholm as well as Adam Farlow and Charles Farnsworth in London.

Explore Our Newsroom